TABLE 2.
Summary of intracellular tenofovir diphosphate and emtricitabine triphosphate pharmacokinetic parameters obtained following drug intake cessationa
| Parameterb | Values (90% CI [CV%]) (n = 18) |
|
|---|---|---|
| Tenofovir diphosphate | Emtricitabine triphosphate | |
| AUC0–24 | 1,456 fmol · h/106 cells (1,302–2,193 [66]) | 87.8 pmol · h/106 cells (79.2–150 [80]) |
| AUC0–168 | 7,495 fmol · h/106 cells (6,792–11,486 [66]) | 273 pmol · h/106 cells (252–440 [70]) |
| Cmax | 92.2 fmol/106 cells (83.8–135 [60]) | 6.15 pmol/106 cells (5.73–10.5 [75]) |
| C24 | 54.0 fmol/106 cells (48.2–87.9 [75]) | 3.07 pmol/106 cells (2.88–5.63 [83]) |
a
Data are presented as geometric means (90% CI). AUC0–24, area under the curve over 24 h postdose; AUC0–168, area under the curve over 168 h postdose; Cmax, maximum concentration; C24, concentration 24 h postdose.
b
Parameters were determined by noncompartmental analysis using concentration-time profiles generated by means of modeling and simulation.